Role of etravirine in the management of treatment-experienced patients with human immunodeficiency virus type 1

References

• PalellaFJJrDelaneyKMMoormanACDeclining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study InvestigatorsN Engl J Med19983388538609516219
   PubMed Web of Science ®Google Scholar
• MocroftALedergerberBKatlamaCDecline in the AIDS and death rates in the EuroSIDA study: an observational studyLancet2003362222912853195
   PubMed Web of Science ®Google Scholar
• SeverePLegerPCharlesMAntiretroviral therapy in a thousand patients with AIDS in HaitiN Engl J Med20053532325233416319381
   PubMed Web of Science ®Google Scholar
• NashDKatyalMBrinkhofMWLong-term immunologic response to antiretroviral therapy in low-income countries: a collaborative analysis of prospective studiesAIDS2008222291230218981768
   PubMed Web of Science ®Google Scholar
• BrinkhofMWBoulleAWeigelRMortality of HIV-infected patients starting antiretroviral therapy in sub-Saharan Africa: comparison with HIV-unrelated mortalityPLoS Med20096e100006619399157
   PubMed Web of Science ®Google Scholar
• HammerSMEronJJJrReissPAntiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panelJAMA200830055557018677028
   PubMed Web of Science ®Google Scholar
• WainbergMAHIV resistance to nevirapine and other non-nucleoside reverse transcriptase inhibitorsJ Acquir Immune Defic Syndr200334 Suppl 1S2S714562852
   PubMed Web of Science ®Google Scholar
• LittleSJHolteSRoutyJPAntiretroviral-drug resistance among patients recently infected with HIVN Engl J Med200234738539412167680
   PubMed Web of Science ®Google Scholar
• VianiRMPeraltaLAldrovandiGPrevalence of primary HIV-1 drug resistance among recently infected adolescents: a multicenter adolescent medicine trials network for HIV/AIDS interventions studyJ Infect Dis20061941505150917083034
   PubMed Web of Science ®Google Scholar
• DescampsDChaixMLAndrePFrench national sentinel survey of antiretroviral drug resistance in patients with HIV-1 primary infection and in antiretroviral-naive chronically infected patients in 2001–2002J Acquir Immune Defic Syndr20053854555215793364
   PubMed Web of Science ®Google Scholar
• LittleSJFrostSDWongJKPersistence of transmitted drug resistance among subjects with primary human immunodeficiency virus infectionJ Virol2008825510551818353964
   PubMed Web of Science ®Google Scholar
• ArriveENewellMLEkoueviDKPrevalence of resistance to nevirapine in mothers and children after single-dose exposure to prevent vertical transmission of HIV-1: a meta-analysisInt J Epidemiol2007361009102117533166
   PubMed Web of Science ®Google Scholar
• Intelence®(etravirine) [Package Insert]Tibotec TherapeuticsRaritan, New Jersey2008 Available at: http://www.intelence-info.com/Accessed Mar 6, 2010
   Google Scholar
• AndriesKAzijnHThielemansTTMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1Antimicrob Agents Chemother2004484680468615561844
   PubMed Web of Science ®Google Scholar
• De CorteBLFrom 4,5,6,7-tetrahydro-5-methylimidazo[4,5,1-jk](1,4) benzodiazepin-2(1H)-one (TIBO) to etravirine (TMC125): fifteen years of research on non-nucleoside inhibitors of HIV-1 reverse transcriptaseJ Med Chem2005481689169615771411
   PubMed Web of Science ®Google Scholar
• Udier-BlagovicMTirado-RivesJJorgensenWLValidation of a model for the complex of HIV-1 reverse transcriptase with nonnucleoside inhibitor TMC125J Am Chem Soc20031256016601712785806
   PubMed Web of Science ®Google Scholar
• DeeksSNonnucleoside reverse transcriptase inhibitor rsesistanceJ Acquir Immune Defic Syndr200126S25S3311264999
   PubMed Web of Science ®Google Scholar
• DasKClarkADJrLewiPJRoles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variantsJ Med Chem2004472550256015115397
   PubMed Web of Science ®Google Scholar
• GruzdevBRakhmanovaADoubovskayaEA randomized, double-blind, placebo-controlled trial of TMC125 as 7-day monotherapy in antiretroviral naive, HIV-1 infected subjectsAIDS2003172487249414600520
   PubMed Web of Science ®Google Scholar
• GazzardBGPozniakALRosenbaumWAn open-label assessment of TMC 125 – a new, next-generation NNRTI, for 7 days in HIV-1 infected individuals with NNRTI resistanceAIDS200317F49F5414685068
   PubMed Web of Science ®Google Scholar
• NadlerJPBergerDSBlickGEfficacy and safety of etravirine (TMC125) in patients with highly resistant HIV-1: primary 24-week analysisAIDS200721F1F1017413684
   PubMed Web of Science ®Google Scholar
• KakudaTNScholler-GyureMWorkmanCSingle- and multiple-dose pharmacokinetics of etravirine administered as two different formulations in HIV-1-infected patientsAntivir Ther20081365566118771049
   PubMed Web of Science ®Google Scholar
• Scholler-GyureMBoffitoMPozniakALEffects of different meal compositions and fasted state on the oral bioavailability of etravirinePharmacotherapy2008281215122218823217
   PubMed Web of Science ®Google Scholar
• Scholler-GyureMKakudaTNVan Solingen-RisteaRBerckmansCDe SmedtGBioavailability of the 100 mg etravirine tablet dispersed in water and of the 25 mg pediatric tablet formulationXVII International AIDS Conference2008 Aug 3–8Mexico City, Mexico Abstract MOPE 0184
   Google Scholar
• KakudaTNWadeJSnoeckEPharmacokinetics and pharmacodynamics of the NNRTI TMC125 in treatment experienced HIV-1 infected Patients: pooled 24-week results of DUET-1 and DUET-215th Conference on Retroviruses and Opportunistic Infections2008 Feb 3–6Boston, MA Abstract 762
   Google Scholar
• Scholler-GyureMKakudaTNRaoofADe SmedtGHoetelmansRMClinical pharmacokinetics and pharmacodynamics of etravirineClin Pharmacokinet20094856157419725591
   PubMed Web of Science ®Google Scholar
• Scholler-GyureMKakudaTNDe SmedtGEffects of hepatic impairment on the steady-state pharmacokinetics of etravirine 200 mg BID: an open-label, multiple-dose, controlled Phase I study in adultsClin Ther20103232833720206790
   PubMed Web of Science ®Google Scholar
• MadrugaJVCahnPGrinsztejnBEfficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trialLancet2007370293817617270
   PubMed Web of Science ®Google Scholar
• LazzarinACampbellTClotetBEfficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebocontrolled trialLancet2007370394817617271
   PubMed Web of Science ®Google Scholar
• KatlamaCHaubrichRLalezariJEfficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trialsAIDS2009232289230019710593
   PubMed Web of Science ®Google Scholar
• AndersonMSKakudaTNHanleyWMinimal pharmacokinetic interaction between the human immunodeficiency virus nonnucleoside reverse transcriptase inhibitor etravirine and the integrase inhibitor raltegravir in healthy subjectsAntimicrob Agents Chemother2008524228423218838586
   PubMed Web of Science ®Google Scholar
• RamanathanSKakudaTNMackRWestSKearneyBPPharmacokinetics of elvitegravir and etravirine following coadministration of ritonavir-boosted elvitegravir and etravirineAntivir Ther2008131011101719195326
   PubMed Web of Science ®Google Scholar
• Scholler-GyureMKakudaTNVan Solingen-RisteaRPharmacokinetic interaction between etravirine and fluconazole or voriconazole in HIV-negative volunteers49th Interscience Conference on Antimicrobial Agents and Chemotherapy2009 Sep 12–15San Francisco, CA Abstract A1-1299
   Google Scholar
• BrownKCPaulSKashubaADDrug interactions with new and investigational antiretroviralsClin Pharmacokinet20094821124119492868
   PubMed Web of Science ®Google Scholar
• RuxrungthamKPedroRJLatiffGHImpact of reverse transcriptase resistance on the efficacy of TMC125 (etravirine) with two nucleoside reverse transcriptase inhibitors in protease inhibitor-naive, nonnucleoside reverse transcriptase inhibitor-experienced patients: study TMC125-C227HIV Med2008988389618795960
   PubMed Web of Science ®Google Scholar
• YazdanpanahYFagardCDescampsDHigh rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trialClin Infect Dis2009491441144919814627
   PubMed Web of Science ®Google Scholar
• VingerhoetsJTambuyzerLAzijnHResistance profile of etravirine: combined analysis of baseline genotypic and phenotypic data from the randomized, controlled Phase III clinical studiesAIDS20102450351420051805
   PubMed Web of Science ®Google Scholar
• VingerhoetsJBuelensAPeetersMImpact of baseline NNRTI mutations on the virologic response to TMC125 in the Phase III clinical trials DUET-1 and DUET-2Antivir Ther200712 Suppl 1S34
   Google Scholar
• TambuyzerLAzijnHRimskyLTCompilation and prevalence of mutations associated with resistance to non-nucleoside reverse transcriptase inhibitorsAntivir Ther20091410310919320243
   PubMed Web of Science ®Google Scholar
• CoakleyEChappeyCBenhamidaJBiological and clinical cutoff analysis for etravirine in the PhenoSense HIV assayAntivir Ther200813 Suppl 3A134
   Google Scholar
• BenhamidaJChappeyCCoakleyEParkinNHIV-1 genotype algorithms for prediction of etravirine susceptibility; novel mutations and weighting factors identified through correlations to phenotypeAntivir Ther200813 Suppl 3A142
   Google Scholar
• HaddadMStawiskiEBenhamidaJCoakleyEImproved genotypic algorithm for predicting etravirine susceptibility: comprehensive list of mutations identified through correlation with matched pPhenotype17th Conference on Retroviruses and Opportunistic Infections2010 Feb 16–19San Francisco, CA Abstract 574
   Google Scholar
• PovedaEde MendozaCPatteryTGonzalez MdelMVillacianJSorianoVPhenotypic impact of resistance mutations on etravirine susceptibility in HIV patients with prior failure to nonnucleoside analoguesAIDS2008222395239818981781
   PubMed Web of Science ®Google Scholar
• Sluis-CremerNMooreKRadzioJSonzaSTachedjianGN348I in HIV-1 reverse transcriptase decreases susceptibility to tenofovir and etravirine in combination with other resistance mutationsAIDS20102431731920010074
   PubMed Web of Science ®Google Scholar
• KonigsCFeiterna-SperlingCEspositoSPharmacokinetics and dose selection of etravirine in HIV-infected children between 6 and 17 years, inclusive16th Conference on Retroviruses and Opportunistic Infections2009 Feb 8–11Montreal, Canada Abstract 879
   Google Scholar
• GeboKAMartinSCorbettCDe SmedtGImpact of TMC125 on hospitalizations and hospital related costs: 24-week findings from pooled DUET trialsInternational AIDS Conference2008 Aug 3–8Mexico City, Mexico Abstract TUPE 0237
   Google Scholar
• Scholler-GyureMKakudaTNDe SmedtGA pharmacokinetic study of etravirine (TMC125) co-administered with ranitidine and omeprazole in HIV-negative volunteersBr J Clin Pharmacol20086650851618492125
   PubMed Web of Science ®Google Scholar